Skip to main content

Myositis

204 pts w/ dermatomyositis/polymyositis Rx w/ IV early pulse steroids(IVMP) or IVIG. IVMP & IVMP+IVIG was assoc w/ 56-58% incr odds of complete response. Pulse IVMP+IVIG incr risk of steroid D/C. Early IVMP/IVIG=no impact on mortality https://t.co/yRFJgos8Qq

Dr. John Cush @RheumNow( View Tweet )

Jul 28, 2021
ICYMI: FDA Approves IVIG in Dermatomyositis https://t.co/BZsl8a6ArW The FDA has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM). https://t.co/VFF0QMqbin
Dr. John Cush @RheumNow( View Tweet )
Jul 24, 2021

FDA Approves IVIG in Dermatomyositis

Jul 20, 2021

The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM).



The manufacturer, Octapharma USA, received

Read Article
Septic arthritis MIMICs (all presenting as acute monoarthritis) - consider: cellulitis, bursitis, abscess, osteonecrosis, gout, pseudogout, Lyme, Osteomyelitis, reactive arthritis, Lyme disease,, Rheumatoid arthritis, & Transient synovitis (kids) https://t.co/uNirAcoBds

Dr. John Cush @RheumNow( View Tweet )

Jul 10, 2021

ICYMI: 2020 Rheumatology Year in Review

Jul 08, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article
ProDERM Study: IVIG in Dermatomyositis--The ProDERM study show that IVIg is safe, effective and superior to placebo in patients with dermatomyositis (DM). https://t.co/HOB8CYn9yc https://t.co/4nNRRhzHVO
Dr. John Cush @RheumNow( View Tweet )
Jul 06, 2021
ProDERM OP0008: IVIG 2g/kg q4w for dermatomyositis vs PBO, open-label extension. TIS score responders 78% vs 43%. IVIG great option: Not immunosuppressive and works fast, watch for headache, pyrexia, nausea, risk of VTE. #EULAR2021 @RheumNow https://t.co/m4CEkg3EyC
Eric Dein @ejdein1( View Tweet )
Jun 02, 2021
ProDERM study (95 pts): RBPCT phase III IVIG 10% is effective in dermatomyositis (2 g/kg over 2-5 days q4 weeks. (common AEs: HA, fever, nausea most common AEs, rare SAE include thrombosis, LoC, hypoesthesia). Dr. R Aggarwal Abstr#OP008 #EULAR2021 @RheumNow https://t.co/ScTdUySxOl
Jun 02, 2021

RheumNow Podcast – BandAids for Rheumatologists (5.14.2021)

May 14, 2021

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com - a website for rheumatologists, by rheumatologists.



We love Rheumatology!




  1. CDC study from 33 sites, 25 states showed vaccine efficacy (against Sx COVID) in HCP was 82% with ONEdose

Read Article

New, Improved Therapy for Pompe Disease

Apr 16, 2021

Researchers from the University of Cincinnati Gardner Neuroscience Institute will present data on a new treatment for Pompe disease at the American Academy of Neurology on April 20th; the results show that treatment with avalglucosidase alfa yielded substantial clinical improvements and a more

Read Article

RheumNow Podcast – Combination Biologics

Apr 16, 2021

Dr. Jack Cush serves up this week's news and articles from RheumNow.com.

Read Article

RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)

Apr 02, 2021

Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.

Read Article
2127 suspected myositis patients assayed for myositis Abs, ~1% tested positive for SAE Abs (small ubiquitin-like modifier (SUMO) activating enzyme) - present w/ rash first, followed by myositis, extramuscular involvement, sm risk for coincident cancer https://t.co/1f0GTcpdIo

Dr. John Cush @RheumNow( View Tweet )

Mar 30, 2021
News Feature: MDA-5 Antibodies and Juvenile Dermatomyositis https://t.co/vxyXZyO0gs https://t.co/GgzhnhlmdR
Dr. John Cush @RheumNow( View Tweet )
Mar 19, 2021

MDA-5 Antibodies and Juvenile Dermatomyositis

Mar 17, 2021

A multicentre, retrospective study examined MSA profiles (by immunoprecipitation) from 96 juvenile idiopathic inflammatory myopathies (JIIM) at nine pediatric rheumatology centres in Japan. MSA were found in 85 of 96 cases with over 90% of patients having one of the following three MSA types

Read Article

RheumNow Podcast – Sweet Lies or Hard Truths? (2.26.2021)

Feb 26, 2021

Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.

Read Article
Other than anti-tRNA synthetase Abs, there are several new Abs associated with PM/DM @UTSWNews @UTSWInternalMed https://t.co/EttRB3YYHm
Dr. John Cush @RheumNow( View Tweet )
Feb 25, 2021
Classic path findings in dermatomyositis @UTSWNews @UTSWInternalMed https://t.co/W61OveDSwG
Dr. John Cush @RheumNow( View Tweet )
Feb 25, 2021
An unsual type of adult polymyositis that is not usually steroid responsive - Polymyositis with mitochondrial abnormalities - older patients +COX staining, slow progression. @UTSWNews @UTSWInternalMed https://t.co/2tv1R3e9Qg
Dr. John Cush @RheumNow( View Tweet )
Feb 25, 2021
Rheumatology Grand Rounds with Dr. Dennis Burns - lecturing on neuropathology of inflammatory myositis. Not all Muscle Bxs are positive, estimated sampling error w/ normal findings in 10-15% @UTSWNews @UTSWInternalMed https://t.co/Xm73GuMa3j
Dr. John Cush @RheumNow( View Tweet )
Feb 25, 2021
High Risk Cancer Profiling with Inflammatory Myositis A recent metanalysis of studies suggest you may be able to use certain clinical factors to stratify cancer risk in patients with idiopathic inflammatory myopathies (IIMs). https://t.co/TjmdGtdDQG https://t.co/tlfVU031fY
Dr. John Cush @RheumNow( View Tweet )
Feb 19, 2021

High Risk Cancer Profiling with Inflammatory Myositis

Feb 18, 2021

A recent metanalysis of studies suggest you may be able to use certain clinical factors to stratify cancer risk in patients with idiopathic inflammatory myopathies (IIMs).

Read Article

RheumNow Podcast – Don’t Hold the Benlysta, Take the Vaccine (1.22.2021)

Jan 22, 2021

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, with more than a dozen items to discuss on this week's podcast.

Read Article
Canadian lupus cohort of 560 SLE pts without myositis at baseline. Over time, only 5 pts developed myositis (after mean 8.5 yrs). Incidence = 1.05 per 1000 PYs. Arthritis, Raynauds, -Sm Abs were common, but only non-Whites had increased risk of myositis. https://t.co/fzWhUADjMz

Dr. John Cush @RheumNow( View Tweet )

Jan 21, 2021
44 pts of Inclusion body myositis were randomized to either PBO or sirolimus 2 mg/d. At 12 mos there were no signif differences betw groups for motor strength , but sirolimus had more SAEs (45 vs 27%); yet sirolimus had better HAQ, FVC & 6-min walk times. https://t.co/YhnRTnaGFl

Dr. John Cush @RheumNow( View Tweet )

Jan 18, 2021
×